{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:06:10Z","timestamp":1773425170453,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10637-017-0485-5","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T03:16:22Z","timestamp":1498619782000},"page":"147-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chemotherapy-induced cardiomyopathy caused by Pemetrexed"],"prefix":"10.1007","volume":"36","author":[{"given":"Takuya","family":"Oyakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"485_CR1","doi-asserted-by":"publisher","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","volume":"23","author":"JD Floyd","year":"2005","unstructured":"Floyd JD, Nguyen DT, Lobins RL et al (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685\u20137696","journal-title":"J Clin Oncol"},{"key":"485_CR2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: \u2002the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"485_CR3","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231\u20132247","journal-title":"J Am Coll Cardiol"},{"key":"485_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589\u20131597","journal-title":"J Clin Oncol"},{"key":"485_CR5","first-page":"1194","volume":"17","author":"JJ Rusthoven","year":"1999","unstructured":"Rusthoven JJ, Eisenhauer E, Butts C et al (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol 17:1194\u20131199","journal-title":"National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol"},{"key":"485_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0344-0338(86)80079-6","volume":"181","author":"H Kajihara","year":"1986","unstructured":"Kajihara H, Yokozaki H, Yamahara M et al (1986) Anthracycline induced myocardial damage. An analysis of 16 autopsy cases. Pathol Res Pract 181:434\u2013441","journal-title":"Pathol Res Pract"},{"key":"485_CR7","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1592\/phco.2005.25.9.1271","volume":"25","author":"A Perez-Verdia","year":"2005","unstructured":"Perez-Verdia A, Angulo F, Hardwicke FL et al (2005) Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 25:1271\u20131276","journal-title":"Pharmacotherapy"},{"key":"485_CR8","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1056\/NEJM199804093381507","volume":"338","author":"GN Welch","year":"1998","unstructured":"Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042\u20131050","journal-title":"N Engl J Med"},{"key":"485_CR9","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900\u20132902","journal-title":"J Clin Oncol"},{"key":"485_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/HCO.0000000000000361","volume":"32","author":"R Moudgil","year":"2017","unstructured":"Moudgil R, Haddad H (2017) Chemotherapy-related cardiac dysfunction: grey area in type I and type II classification. Curr Opin Cardiol 32:181\u2013188","journal-title":"Curr Opin Cardiol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0485-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:12:26Z","timestamp":1678511546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0485-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["485"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0485-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]},"assertion":[{"value":"24 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Takuya Oyakawa reports personal fees from Bristol-Myers Squibb, personal fees from Sumitomo Dainippon Pharma, personal fees from Pfizer. Kei Iida reports personal fees from Ono Pharmaceutical Co, Ltd., personal fees from Bristol-Myers, personal fees from Daiichi Sankyo, personal fees from Toa eiyo Ltd. Hirotsugu Kenmotsu reports grants and personal fees from AstraZeneca K.K., grants and personal fees from Chugai Pharmaceutical Co, Ltd., personal fees from Ono Pharmaceutical Co, Ltd., personal fees from Bristol-Myers K.K, grants and personal fees from Boeringer Ingelheim, personal fees from Eli Lilly K.K, personal fees from Kyowa Hakko Kirin Co., Ltd. Masatoshi Kusuhara has nothing to disclose. Takashi Sugino has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding sources"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}